Hypovolemic Shock Market

DelveInsight's "Hypovolemic Shock Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the hypovolemic shock, historical and forecasted epidemiology as well as the hypovolemic shock market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

 

The hypovolemic shock market report provides current treatment practices, emerging drugs, hypovolemic shock market share of the individual therapies, current and forecasted hypovolemic shock market size from 2019 to 2032 segmented by seven major markets. The report also covers current hypovolemic shock treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan

 

Study Period: 2019–2032

Hypovolemic Shock Disease Understanding and Treatment Algorithm

The DelveInsight’s hypovolemic shock market report gives a thorough understanding of hypovolemic shock by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Hypovolemic shock is an acute disturbance in the circulation leading to an imbalance between oxygen supply and demand in the tissues, caused by a decline in circulating blood volume or it can be described as a condition of inadequate organ perfusion caused by loss of intravascular volume, usually acute.

Hypovolemic shock occurs as a result of decreased circulating blood volume, most commonly from acute hemorrhage. Blood loss can be due to bleeding from cuts, bleeding from other injuries and internal bleeding.

Hypovolemic shock as a result of extracellular fluid loss can be of the etiologies such as gastrointestinal losses, renal losses, skin losses, and sequestration. The most frequent cause of hypovolemic shock is trauma. It may also be the result of fluid sequestration within the abdominal viscera or peritoneal cavity. The severity of hypovolemic shock depends not only on the volume deficit loss, the time frame within which the fluid is lost, but also on the age and pre-injury health status of the individual.

The first changes in vital signs seen in hypovolemic shock include an increase in diastolic blood pressure with narrowed pulse pressure. As volume status continues to decrease, systolic blood pressure drops. As a result, oxygen delivery to vital organs is unable to meet oxygen demand. Cells switch from aerobic metabolism to anaerobic metabolism, resulting in lactic acidosis. As sympathetic drive increases, blood flow is diverted from other organs to preserve blood flow to the heart and brain. This propagates tissue ischemia and worsens lactic acidosis.

Patients with hypovolemic shock have severe hypovolemia with decreased peripheral perfusion. If left untreated, these patients can develop ischemic injury of vital organs, leading to multi-system organ failure. Hypovolemic shock leading to ischemia-reperfusion triggers an inflammatory response, particularly in the gut. The syndrome also is characterized by a diminished immunologic defense.

The first factor to be considered is whether the hypovolemic shock has resulted from hemorrhage or fluid losses, as this will dictate treatment. When etiology of hypovolemic shock has been determined, replacement of blood or fluid loss should be carried out as soon as possible to minimize tissue ischemia.

 

Hypovolemic Shock Disease Diagnosis

History and physical can often make the diagnosis of hypovolemic shock. A history of trauma, overt bleeding, or recent surgery is present for patients with hemorrhagic shock. For the non-hemorrhagic hypovolemic shock due to fluid losses, history and physical should attempt to identify possible GI, renal, open wounds, skin, or third-spacing as a cause of extracellular fluid loss. Symptoms of hypovolemic shock can be related to volume depletion, electrolyte imbalances, or acid-base disorders that accompany hypovolemic shock. Additionally, various laboratory values can be abnormal in hypovolemic shock. Patients can have increased BUN and serum creatinine due to pre-renal kidney failure. Also, hypernatremia or hyponatremia can result, as can hyperkalemia or hypokalemia.

 

Hypovolemic Shock Disease Treatment

Management of hypovolemia involves assessing and treating the underlying cause, identifying electrolyte and acid-base disturbances, and assessing and treating the volume deficit, all of which influence the choice of fluid and rate at which it should be administered. Clinicians should identify the etiology (or etiologies) contributing to hypovolemia so that therapies can be directed at the underlying cause of volume loss. Fluid resuscitation is the mainstay of therapy in patients with severe hypovolemia. Temporary measures to control bleeding such as pressure, tourniquets, and pelvic binders may be applied to help with immediate hemorrhage control until definitive management can stop the bleeding. In traumatic bleeding, patients should be triaged per the ABCDE’s of Advanced Trauma Life Support (ATLS).

Red cell concentrates (RCC) indicated for Hemorrhagic shock, traumatic hemorrhagic shock and all other types of shock in patients with signs of anemic hypoxia, replace lost red blood cells, increase blood oxygen concentration, increase blood coagulability. Platelet concentrates (PC) which replaces platelets, is generally used for the treatment of Trauma and hemorrhage-induced coagulopathy with thrombocytopenia.

Fresh frozen plasma (FFP) replaces coagulation factors and volume that can be used for various types of shock such as hypovolemic shock. Coagulation factors (fibrinogen, PPSB = F II, VII, IX and X) selectively replaces individual factors after loss/use of vitamin K inhibitor and NOAC-induced hemorrhage.

Crystalloid fluid resuscitation is preferred over colloid solutions for severe volume depletion not due to bleeding. The type of crystalloid used to resuscitate the patient can be individualized based on the patients' chemistries, estimated volume of resuscitation, acid/base status, and physician or institutional preferences.

In addition to blood products, products that prevent the breakdown of fibrin in clots, or antifibrinolytics, have been studied for their utility in the treatment of hemorrhagic shock in the trauma patient.  Several antifibrinolytics have been shown to be safe and effective in elective surgery. Further, surgical management should be undertaken as soon as possible using the damage control surgery (DCS) approach. Persisting hypotension, especially in patients with head trauma, should be rectified with prompt administration of a vasoconstrictor (e.g., norepinephrine) to achieve a systolic arterial pressure (SAP) that equals to 90 mmHg

Hypovolemic Shock Epidemiology

The hypovolemic shock epidemiology section provides insights about historical and current hypovolemic shock patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

According to the study conducted by Sharven et al, 62.2% of massive transfusions at a level 1 trauma center were due to traumatic injury. In this study, 75% of blood products used were related to traumatic injury. Elderly patients are more likely to experience hypovolemic shock due to fluid losses as they have a less physiologic reserve.

As per Trauma Registry of the German Trauma Society, the incidence of gastrointestinal hemorrhage in Germany is around 100,000 patients per year, of whom roughly 10,000 suffer hypovolemic shock. These figures, together with those for the remaining subtypes of hypovolemic shock such as Hemorrhagic shock, Traumatic hemorrhagic shock, and others lead to a total of about 50,000 patients per year.

According to Sharven Taghavi et al., the annual incidence of shock of any etiology is 0.3 to 0.7 per 1000, with hemorrhagic shock being most common in the intensive care unit.

The disease epidemiology covered in the report provides historical as well as forecasted hypovolemic shock epidemiology is segmented as Incident cases of Hypovolemic Shock and Treatable cases of Hypovolemic Shock in the 7MM covering the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan from 2019 to 2032.

 

Country Wise-Hypovolemic Shock Epidemiology

This section provides glimpse of the hypovolemic shock epidemiology in the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan.

 

Hypovolemic Shock Drug Chapters

The drug chapter segment of the hypovolemic shock report encloses the detailed analysis of hypovolemic shock marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the hypovolemic shock clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Hypovolemic Shock Emerging Drugs

Limited late-stage pipeline activities has been observed in hypovolemic shock, as per ClinicalTrials.gov. However, notable progress has emerged in the research pipelines for the prevention and treatment of hypovolemic shock. Companies across the globe have taken the initiative working towards the development of suitable options for hypovolemic shock. Key players, such as Pharmazz, Vivacelle Bio, Perfusion Medical, and others are involved in developing treatment for hypovolemic shock.

PEG-20k (Perfusion Medical) is a breakthrough IV solution for restoration of tissue perfusion invented at the Virginia Commonwealth University (VCU) School of Medicine. PEG-20k shows potential to be a disruptive solution for addressing severe blood loss (hemorrhagic shock) and related medical conditions. The major mechanism of action of PEG-20k IV solution in treating severe hypovolemic shock is to increase tissue perfusion to facilitate rapid transfer of oxygen into oxygen starved tissues and organs. This is accomplished by reversing the metabolic cell and tissue swelling that occurs during shock, which causes no reflow by capillary compression.

Vivacelle Bio is currently working on two formulations; VBI-S (Vivacelle) and VBI-1. This new class of resuscitation fluids has restored blood pressure, circulating volume and thereby increased survival in animal models of hypovolemia. VBI-1 is a suspension of lipid droplets which form nanoparticles and represents a new paradigm for use in fluid resuscitation, safely restoring blood vessel volume and reversing the effects of hypovolemia. It is a colloid non-blood volume expander that appears to be two to three times more effective than the standard treatment for hypovolemia due to hemorrhagic shock. The drug received FDA clearance to enroll patients into its Phase IIa trial for severe blood loss and/or raising blood pressure in Hypovolemic patients. VBI-S is a phospholipid-based nanoparticle fluid. Currently, company is conducting its phase IIa for the Hypovolemic Septic Shock Patients.

PMZ-2010 (Centhaquine) (Pharmazz) acts through a unique mechanism of action that is completely different from any of the existing drugs or investigational products. It increases blood pressure and cardiac output by augmenting venous blood return to the heart (alpha2B-adrenergic stimulation), and it enhances tissue perfusion by arterial dilatation (alpha1-adrenergic block). Enhancing tissue perfusion is a significant advantage in reducing the adverse effects of existing vasopressors. Moreover, it does not act on beta-adrenergic receptors, and therefore the risk of arrhythmias is mitigated. The company submitted a request for pre-IND meeting with US FDA in Oct 2019 and was granted a type C face to face meeting in Dec 2019.

 

Note: Detailed emerging therapies assessment will be provided in the full report of hypovolemic shock

Hypovolemic Shock Market Outlook

In the past few decades, research into hypovolemic shock has increased tremendously. With it, understanding of hypovolemic shock pathophysiology and treatment options has improved as well. Drugs targeting specific ion channels are approaching the early stages of clinical investigation. There are also new and exciting areas of hypovolemic shock research such as gene therapy, cell therapy, and microRNAs and their function on tissue remodeling. With the aging population and ever increasing prevalence of hypovolemic shock, optimized treatment plans for individuals with hypovolemic shock are essential. However, while advances in technologies have helped elucidate many aspects of hypovolemic shock, many mysteries remain. With continued research and into hypovolemic shock, the researchers can expect more effective drug therapies and ablation techniques to be developed soon.

The other factors that shall further expedite the growth of the hypovolemic shock market include its increasing morbidity rate and increasing awareness about available treatments during the forecast period (2019–2032). A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for hypovolemic shock. 

According to DelveInsight, hypovolemic shock market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Analyst Commentary

• The pipeline of hypovolemic shock is very robust, many potential therapies are being investigated for the treatment of hypovolemic shock, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the hypovolemic shock market in the 7MM. Aside from that, the market size of hypovolemic shock may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
• The market growth of hypovolemic shock may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

 

Hypovolemic Shock Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the hypovolemic shock market or expected to get launched in the market during the study period 2019-2032. The analysis covers hypovolemic shock market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Note: Detailed emerging therapies assessment will be provided in full report of hypovolemic shock.

 

Hypovolemic Shock Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses hypovolemic shock key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for hypovolemic shock emerging therapies.

 

Reimbursement Scenario in Hypovolemic Shock

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the hypovolemic shock domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or hypovolemic shock market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

 

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the hypovolemic shock Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

 

Scope of the Report

• The report covers the descriptive overview of hypovolemic shock, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the hypovolemic shock epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for hypovolemic shock are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the hypovolemic shock market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global hypovolemic shock market

 

Report Highlights

• In the coming years, the hypovolemic shock market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence hypovolemic shock R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• Major players are involved in developing therapies for hypovolemic shock. The launch of emerging therapies will significantly impact the hypovolemic shock market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for hypovolemic shock
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Hypovolemic Shock Report Insights

• Patient Population
• Therapeutic Approaches
• hypovolemic shock Pipeline Analysis
• hypovolemic shock Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

 

Hypovolemic shock Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Hypovolemic Shock Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Hypovolemic ShockHypovolemic ShockHypovolemic ShockHypovolemic ShockHypovolemic ShockHypovolemic ShockHypovolemic ShockHypovolemic ShockHypovolemic ShockDrugs Uptake

 

Hypovolemic Shock Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

 

Key Questions

 

Market Insights:

• What was the hypovolemic shock drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the hypovolemic shock total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest hypovolemic shock market size during the forecast period (2019-2032)?
• At what CAGR, the hypovolemic shock market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the hypovolemic shock market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the hypovolemic shock market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of hypovolemic shock?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan?
• What is the historical hypovolemic shock patient pool in seven major markets covering the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of hypovolemic shock in seven major markets covering the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about hypovolemic shock?
• Out of all 7MM countries, which country would have the highest prevalent population of hypovolemic shock during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the hypovolemic shock treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of hypovolemic shock in the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan?
• What are the hypovolemic shock marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of hypovolemic shock?
• How many therapies are in-development by each company for hypovolemic shock treatment?
• How many are emerging therapies in mid-stage, and late stage of development for hypovolemic shock treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the hypovolemic shock therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for hypovolemic shock and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for hypovolemic shock?
• What are the global historical and forecasted markets of hypovolemic shock?

 

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the hypovolemic shock market
• Organize sales and marketing efforts by identifying the best opportunities for hypovolemic shock in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the hypovolemic shock market
• To understand the future market competition in the hypovolemic shock market
• DelveInsight's " Hypovolemic Shock Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the hypovolemic shock, historical and forecasted epidemiology as well as the hypovolemic shock market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
• The hypovolemic shock market report provides current treatment practices, emerging drugs, hypovolemic shock market share of the individual therapies, current and forecasted hypovolemic shock market size from 2019 to 2032 segmented by seven major markets. The report also covers current hypovolemic shock treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.